Oncology company ORIC Pharmaceuticals has completed a $50m Series C preferred stock financing to support advancement of its ORIC-101 against treatment-resistant solid tumours, as well as continued progress on mechanisms of resistance in cancer.

With the new financing, the total equity capital raised by the company has increased to more than $119m.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Fidelity Management & Research Company, Trinitas Capital, Taiho Ventures, and NS Investment are the new investors in the Series C.

The company’s investors, including The Column Group, Topspin Fund, OrbiMed, Memorial Sloan Kettering Cancer Center, EcoR1 Capital, Kravis Investment Partners, and Foresite Capital also participated in the financing.

ORIC-101, the company’s lead asset, is a potent small-molecule inhibitor of the glucocorticoid receptor (GR) and the subject of an ongoing Phase I trial.

“With our Series C financing we are very pleased to have both the continued support of our previous investors and expand our investor base with leading investors.”

ORIC Pharmaceuticals CEO and board member Richard Heyman said: “Treatment-resistant cancers are a large unmet medical need. With our Series C financing we are very pleased to have both the continued support of our previous investors and expand our investor base with leading investors.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Their support, combined with ORIC’s commitment to discovering and developing new therapeutics targeting cancer, allows the company to build on the strong foundation of our co-founders, advisors and internal team, and provides for long-term success.”

The company also plans to pursue clinical development of the inhibitor in patients with treatment-resistant solid tumours combining with immuno-oncology treatments and chemotherapy.

ORIC also plans to use the investment to support its research and pipeline programmes that target mechanisms of resistance in cancer.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact